Caris Life Sciences (CAI) Fundamentals 2026 — Revenue Analysis | SniperIQ

5.48 on the NASDAQ. This SniperIQ fundamentals page covers Caris Life Sciences's valuation, profitability (net margin 3.7%), revenue ($812M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Caris Life Sciences's market cap?

Caris Life Sciences (CAI) has a market capitalization of approximately $4.4B, trading at

5.48 on the NASDAQ. Market cap moves with the live share price.

What is Caris Life Sciences's P/E ratio?

Caris Life Sciences's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Caris Life Sciences?

Caris Life Sciences runs a net profit margin of 3.7%, a gross margin of 68.7%, and an operating margin of 15.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Caris Life Sciences generate?

Caris Life Sciences reported revenue of $812M for fiscal year 2025, with net income of -$538M and earnings per share (EPS) of -1.9. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Caris Life Sciences pay a dividend?

Caris Life Sciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Caris Life Sciences financially healthy?

Caris Life Sciences carries a debt-to-equity ratio of 0.73x and a current ratio of 7.05x, with a market beta of 0.59. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Caris Life Sciences a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Caris Life Sciences (CAI) the key facts are: market cap $4.4B, revenue $812M, 52-week range 14.19-42.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.